Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TriSalus Life SciencesTLSI +0.57%26 Intrinsic Value: Projected FCF is $0.00 as of Aug. 22, 2026. GuruFocus rates TLSI with a GF Score™ of 26/100 and a GF Value™ of $3.77 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 406 Medical Devices & Instruments companies, TriSalus Life Sciences ranks worse than 246305.17% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for TriSalus Life Sciences's Intrinsic Value: Projected FCF or its related term are showing as below:
TLSI's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.5 * Ranked among companies with meaningful Price-to-Projected-FCF only.
TriSalus Life Sciences (NAS:TLSI) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
TriSalus Life Sciences's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
5.27
/
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Intrinsic Value: Projected FCF Related Terms
TriSalus Life Sciences Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Intrinsic Value: Projected FCF Chart
TLSI vs TMCI, SENS, SGHT: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Price-to-Projected-FCF falls into.
TriSalus Life Sciences Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
What does a Intrinsic Value: Projected FCF of $0.00 mean?
TriSalus Life Sciences (TLSI) has a Intrinsic Value: Projected FCF of $0.00 as of Aug. 22, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on TriSalus Life Sciences and its competitors. According to the industry distribution chart, TriSalus Life Sciences ranks #999999 out of 406 companies in the Medical Devices & Instruments industry.
Is TriSalus Life Sciences' Intrinsic Value: Projected FCF too high?
TriSalus Life Sciences' current Intrinsic Value: Projected FCF is $0.00. Based on the distribution chart, TriSalus Life Sciences ranks #999999 out of 406 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Intrinsic Value: Projected FCF compare to TMCI and SENS?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #999999 out of 406 companies for Intrinsic Value: Projected FCF. This places TriSalus Life Sciences in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.50, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Intrinsic Value: Projected FCF is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.77, compared to a current price of $5.27 — trading 39.8% above its estimated fair value. The current Intrinsic Value: Projected FCF is $0.00. TriSalus Life Sciences' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Intrinsic Value: Projected FCF is $0.00 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued.
The current stock price of $5.27 is trading 39.8% above its estimated GF Value™ of $3.77.
GuruFocus considers TriSalus Life Sciences to be Significantly Overvalued.
Key valuation signals for TLSI:
Intrinsic Value: Projected FCF: $0.00
GF Value™: $3.77 vs. price of $5.27 (39.8% above fair value)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
26GF Score
Get the complete analysis for TLSI
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
